Intercept Pharmaceuticals Bookmark and Share

ArticleDateSource
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy PharmaMarch 25, 2014Pharma News - PR Newswire
Intercept Pharmaceuticals To Provide 2013 Update On Clinical Programs For Obeticholic Acid On January 9 January 03, 2014BioSpace - Breaking News
INTERCEPT PHARMACEUTICALS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Intercept Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary DutyDecember 09, 2013Medical Pharma - PR Newswire
Mintz Levin Represents Intercept Pharmaceuticals Inc. in Follow-On Public OfferingJuly 01, 2013Pharma News - Business Wire
Intercept Pharmaceuticals to Present at the JMP Securities Healthcare ConferenceJuly 01, 2013Biotech News - PR Newswire
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional SharesJune 24, 2013Biotech News - PR Newswire
Cerus Initiates Patient Enrollment in European Phase III Clinical Trials for INTERCEPT Red Blood Cells for Acute and Chronic AnemiaJune 11, 2013Pharma News - PharmiWeb
Cerus Initiates Patient Enrollment in European Phase III Clinical Trials for INTERCEPT Red Blood Cells for Acute and Chronic AnemiaJune 11, 2013Biotech News - Business Wire
Intercept Pharmaceuticals Announces Initiation of Phase 2 NASH Trial of OCA in Japan January 08, 2013BioSpace - Breaking News
Intercept Pharmaceuticals Announces Pricing of Initial Public Offering October 11, 2012BioSpace - Breaking News
Cerus to Partner with American Red Cross and Blood Systems Incorporated to Commercialize INTERCEPT Plasma for Thrombotic Thrombocytopenic Purpura (TTP) Orphan IndicationSeptember 11, 2012FDA News - Business Wire
Intercept Pharmaceuticals Files for $75 Million IPO September 05, 2012BioSpace
Intercept Pharma files for $75M IPO to back PhIII liver drug September 05, 2012FierceBiotech
Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public OfferingSeptember 04, 2012Pharma News - PR Newswire
Cerus Announces First INTERCEPT Blood System Customer in TurkeyAugust 07, 2012Biotech News - Business Wire
Cerus Announces First INTERCEPT Platelet System Customer in AustriaApril 18, 2012Biotech News - Business Wire
Cerus Submits Investigational Device Exemption (IDE) Supplement to FDA for Phase III INTERCEPT Red Blood Cell StudyMarch 21, 2012Biotech News - Business Wire
Cerus and Ilex BioTech Report INTERCEPT Platelet and Plasma System Approvals in IsraelFebruary 01, 2012Biotech News - Business Wire
Cerus Announces Contracts for 19 New INTERCEPT Blood System Illuminators in RussiaDecember 06, 2011Biotech News - Business Wire
Intercept nails $165M diabetes pact with ServierAugust 09, 2011FierceBiotech
Intercept Pharmaceuticals, Servier Announce up to $163 Million Agreement for TGR5 Research Program in Type 2 Diabetes August 09, 2011BioSpace
Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 DiabetesAugust 09, 2011Biotech News - PR Newswire
Cerus Corporation and Ilex Biotech LTD Initiate Distribution Agreements for the INTERCEPT Blood System in South Africa and IsraelJune 09, 2011Biotech News - Business Wire
Airport authorities intercept illegal consignment of pain-killersMay 26, 2011Pharmaceutical - Moreover
Dainippon Sumitomo Pharma lands into a deal with Intercept PharmaceuticalApril 04, 2011Pharmaceutical - Moreover
Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary CirrhosisMarch 31, 2011Biotech News - PR Newswire
Intercept lands $315M Asian pact for liver disease drugMarch 30, 2011FierceBiotech
Dainippon Sumitomo Pharma Co., Ltd. and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease; Pays $15 Million and up to $300 Million March 30, 2011BioSpace
Dainippon Sumitomo Pays Intercept $15M for License to Phase III-Stage Liver Disease DrugMarch 30, 2011Inside Industry - Gen
Dainippon Sumitomo, Intercept in Liver Drug PactMarch 30, 2011Contract Pharma
Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver DiseaseMarch 30, 2011Pharma News - PR Newswire
Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASHMarch 29, 2011Pharma News - PR Newswire
Cerus Corporation's INTERCEPT Plasma Granted Orphan Drug Designation for Treatment of Thrombotic Thrombocytopenic Purpura (TTP) February 16, 2011BioSpace - Breaking News
Cerus' INTERCEPT Plasma Granted Orphan Drug Designation for Treatment of Thrombotic Thrombocytopenic Purpura (TTP)February 16, 2011FDA News - Business Wire
Cerus’ INTERCEPT Blood System for Plasma Receives Swiss ApprovalNovember 16, 2010Biotech News - Business Wire
CSL Limited and Cerus Corporation Enter Distribution Agreement for the INTERCEPT Blood System in Australia and New ZealandOctober 12, 2010Pharma News - Business Wire
Cerus' INTERCEPT Platelet System Succeeds in 3-Year French StudySeptember 27, 2010Pharma News - Business Wire
Whittemore Peterson Institute and Cerus Corporation Announce Inactivation of XMRV in Platelets and Red Blood Cells by the INTERCEPT Blood System September 07, 2010BioSpace - Breaking News
Whittemore Peterson Institute and Cerus Announce Inactivation of XMRV in Platelets and Red Blood Cells by the INTERCEPT Blood SystemSeptember 07, 2010Biotech News - Business Wire
Cerus and the Swiss Red Cross Report Successful Outcome of INTERCEPT Blood System Platelet StudySeptember 02, 2010Biotech News - Business Wire
Cerus Corporation Signs Agreement to Acquire INTERCEPT Blood System Asian Commercial Rights from BioOne August 25, 2010BioSpace - Breaking News
Cerus Signs Agreement to Acquire INTERCEPT Blood System Asian Commercial Rights from BioOneAugust 24, 2010Pharma News - Business Wire
Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)July 28, 2010Biotech News - PR Newswire
Whittemore Peterson Institute and Cerus Confirm Inactivation of XMRV by the INTERCEPT Blood SystemMay 18, 2010Biotech News - Business Wire
Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL Company Also Presents Data on Novel Dual FXR/TGR5 Agonist INT-767 April 13, 2010BioSpace - Breaking News
Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASLApril 13, 2010Clinical Trials - PR Newswire
Intercept Pharmaceuticals, Inc.: Series B $25MApril 12, 2010OnBioVC
Cerus Signs Agreement with Swiss Red Cross for Deployment of the INTERCEPT Blood System for PlateletsMarch 31, 2010Biotech News - Business Wire
Data Presented at International Haemovigilance Seminar Confirm Safety of Cerus' INTERCEPT Blood System for Platelets and PlasmaFebruary 17, 2010Clinical Trials - Business Wire
Cerus to Collaborate with French National Transfusion Service on INTERCEPT Red Blood Cell DevelopmentFebruary 09, 2010Biotech News - Business Wire
Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood CellsFebruary 09, 2010Biotech News - Business Wire
Intercept Pharmaceuticals Raises $25 Million Series B Financing; Assumes Role of Chairman January 25, 2010BioSpace - Breaking News
Intercept Pharmaceuticals Scores $25M in Series B FinancingJanuary 25, 2010GEN News Highlights
Intercept Pharma hauls in $25M Series BJanuary 25, 2010FierceBiotech
Intercept Pharmaceuticals Raises $25 Million Series B FinancingJanuary 25, 2010Biotech News - PR Newswire
Cerus Corporation Reports Positive Outcome in European Study of 7-Day INTERCEPT PlateletsJanuary 14, 2010Biotech News - Business Wire



View all the latest news